Особенности лечения курящих пациентов с артериальной гипертонией

1. Шальнова С.А. Деев А.Д, Оганов Р.Г. Факторы влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваск. тер. и профилак. 2005; 1: 4–9.
2. Hughes JR. Four beliefs that may impede progress in the treatment of smoking.Tob Control 1999; 8: 323–6.
3. Rosenberg L, Kaufman DW, Heirlich SP et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313: 1511–14.
4.Heyden S, Schneider KA, Fodor JG. Smoking habits and antihypertensive treatment. Nephron 1987; 47 (Suppl 1): 99–103.
5. Barry J, Mead K, Nabel EG. Effect of smoking on the activity of ischemic heart disease. JAMA 1989, 261 (3): 398–402.
6. Bang LE, Buttenschon L, Kristensen KS et al. Do we undertreat hypertensive smokers? A comparison between smoking and non-smoking hypertensives. Circulation 1994; 90 (1): 248–53.
7. Journath G, Nilsson PM, Petersson U et al. Hypertensive smokers have a worse cardiovascular risk profile than non-smokers in spite of treatment-a national study in Sweden. Blood Press. 2005; 14 (3): 144–50.
8. Марцевич С.Ю., Шальнова С.А.Деев А.Д. и др. Исследование ПРОЛОГ: основные итоги и руководство к действию. Кардиоваск. тер. и профилак. 2006; 6: 23–6.
9. Fox KM. Smoking, catecholamines and the ischemic myocardium. Postgrad Med 1988; 29 (spec. no): 148–51.
10. Лукина Ю.В. Лекарственные препараты и курение. Рационал. фармакотер. в кардиол. 2005; 1: 31–6.
11. Zeiher АM, Schachinger V, Мinnenf. Long-term cigarette smoking impairs endothelium independent coronary arterial vasodilator function. Circulation 1995; 92: 1094–100.
12. Heitzer T, Via Herttuala S, Luoma L et al. Cigarette smoking potentiates endothelial disfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation. 1996; 93: 1346–53.
13. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995–1001.
14. Kumar KV, Das UN. Are free radicals involved in the pathobiology of human essential hypertension? Free Radic Res Commun 1993; 19: 59–66.
15. Lyons D. Impairment and restoration of nitric oxide – dependent vasodilatation in cardiovascular disease. Int J Cardiol 1997; 62 (Suppl 2): S 101–9.
16. Mancini G, Henry G, Mancaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary disease. The TREND (Trial on reversing Endothelial Dysfunction) study. Circulation 1996; 94: 258–65.
17. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative Study of ACE-inhibition, Angiotensin II Antagonism and Calcium Channel Blockade on Flow-mediated Vasodilation in Patients with coronary Disease (BANFF Study). J Amer Coll Cardiol 2000; 35 (1): 60–6.
18. Lee AF, Dick JB, Bonnar CE et al. Lisinopril improves arterial function in hyperlipidaemia. Clin Sci (Lond) 1999; 96 (5): 441–8.
19. Butler R, Morris AD, Struthers AD. Lisinopril improves endothelial function in chronic cigarette smokers. Clin Sci (Lond). 2001; 101 (1): 53–8.
20.Kotamaki M, Manninen V, Laustiola KA. Enalapril versus atenolol in the treatment of hypertensive smokers. Eur J Сlin Pharmacol 1993; 44 (1): 13–7.
21. Celermajer DS, Sorensen KE, Gooch VM et al. Non – invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111–5.

Д.В.Небиеридзе, Ф.А.Папова, А.С.Сафарян,
В.Д.Саргсян, Н.Л.Винницкая